2018
Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models
Toubai T, Rossi C, Tawara I, Liu C, Zajac C, Oravecz-Wilson K, Peltier D, Sun Y, Fujiwara H, Riwes M, Henig I, Kim S, Suto M, Ishizawa K, Reddy P. Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models. Blood 2018, 132: 4529-4529. DOI: 10.1182/blood-2018-99-114634.Peer-Reviewed Original ResearchGraft-versus-host diseaseAcute graft-versus-host diseaseGVHD clinical scoresBone marrow transplantationT cell-independent mechanismDonor T cellsSR-GVHDHuman leukocyte antigenSplenic T cellsT cellsSteroid-refractoryClinical scoresAllo-HCTBone marrowMurine modelAbstract Acute graft-versus-host diseaseGraft-versus-host disease target organsSteroid-refractory graft-versus-host diseaseProgressive graft-versus-host diseaseRefractory graft-versus-host diseaseGut epithelial cellsMurine bone marrow transplantationHistopathological scoresWeight lossDays of DEX treatment
2013
Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation
Toubai T, Sun Y, Luker G, Liu J, Luker K, Tawara I, Evers R, Liu C, Mathewson N, Malter C, Nieves E, Choi S, Murphy K, Reddy P. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood 2013, 121: 4231-4241. PMID: 23520337, PMCID: PMC3656455, DOI: 10.1182/blood-2012-05-432872.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsTumor-specific antigensGVT responseAllo-HCTAPC subsetsDendritic cellsExperimental allogeneic bone marrow transplantationHost-derived antigen-presenting cellsAllogeneic bone marrow transplantationAllogeneic hematopoietic cell transplantationAlloantigen-specific responsesHost-derived CD8Donor T cellsHematopoietic cell transplantationBone marrow transplantationRelevant murine modelStimulation of TLR3Host diseaseTumor effectMarrow transplantationCell transplantationTumor responseSerious toxicityT cellsOptimal graft
2011
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
Hashimoto D, Chow A, Greter M, Saenger Y, Kwan W, Leboeuf M, Ginhoux F, Ochando J, Kunisaki Y, van Rooijen N, Liu C, Teshima T, Heeger P, Stanley E, Frenette P, Merad M. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. Journal Of Experimental Medicine 2011, 208: 1069-1082. PMID: 21536742, PMCID: PMC3092347, DOI: 10.1084/jem.20101709.Peer-Reviewed Original ResearchConceptsDonor allogeneic T cellsDonor T cell expansionAllogeneic hematopoietic cell transplantationAllogeneic T cellsHematopoietic cell transplantationAllo-HCTT cell expansionT cellsAcute GVHDCell transplantationHost macrophagesHost antigen-presenting cellsMacrophage poolPotential prophylactic therapyAlloreactive T cellsAntigen-presenting cellsAcute graftGVHD morbidityGVHD mortalityHost DCsHost diseaseProphylactic therapyRecipient miceGVHDRecipient macrophages